Company intelligence / Profile preview

PrimeGen Global

Irvine, California, United States

Ownership: Private
Development stage: Other

Overview

PrimeGen Global was a biotechnology company focused on the development of regenerative medicine therapies using adult-derived pluripotent stem cells. The company's core technology, PrimeCell, aimed to identify and transform germline stem cells into a pluripotent state without the use of embryos. This platform was designed to create patient-specific cells for the treatment of various conditions, including heart disease and neurological disorders. Although a pioneer in the stem cell reprogramming space during the mid-2000s, the company is no longer active in clinical development.

Therapeutic areas: CardiovascularNeurologyOtherMetabolic Disorders
Modalities: Stem cell therapyInduced pluripotent stem cell derived therapy
Industry: Biotech

Beyond the preview

Go deeper on PrimeGen Global.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PrimeGen Global.

Explore the full profile